Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for GFC Life Science Co., Ltd. (388610:KRX), powered by AI.
GFC Life Science Co., Ltd. is currently trading at ₩6,560. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for GFC Life Science Co., Ltd. on Alpha Lenz.
GFC Life Science Co., Ltd.'s P/E ratio is 62.9.
“GFC Life Science Co., Ltd. trades at a P/E of 62.9 (premium valuation) with modest ROE of 3.2%.”
Ask for details →GFC Life Science Co., Ltd. is a company that operates primarily in the biotechnology and pharmaceutical industries. The firm is engaged in the development, manufacture, and sale of various life science products and technologies. Its primary function is to enhance the quality and effectiveness of healthcare and medical research through innovative solutions. The company is focused on a broad range of applications, including biotechnological advancements, pharmaceutical manufacturing, and healthcare technology. GFC Life Science Co., Ltd. plays a significant role in these industries by providing breakthrough products that support drug discovery, medical diagnostics, and therapeutic developments. It is actively involved in both the domestic and international markets, catering to the growing demand for advanced medical technologies and pharmaceuticals. With an emphasis on research and development, GFC Life Science Co. continues to contribute to the advancement of medical sciences, impacting various sectors such as healthcare, agriculture, and environmental protection. The company's contributions are critical in a market increasingly driven by technological advancements and the need for sustainable healthcare solutions, making it a pivotal player in the life sciences sector.
“GFC Life Science Co., Ltd. trades at a P/E of 62.9 (premium valuation) with modest ROE of 3.2%.”
Ask for details →GFC Life Science Co., Ltd. (ticker: 388610) is a company listed on KRX in the Unknown sector (Unknown). Market cap is $34.9B.
The current price is ₩6,560 with a P/E ratio of 62.9x and P/B of 1.47x.
ROE is 3.20% and operating margin is 2.18%. Annual revenue is $17.7B.